LeMaitre Vascular, Inc. (LMAT) Stake Lifted by Albion Financial Group UT

Albion Financial Group UT lifted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,461 shares of the medical instruments supplier’s stock after purchasing an additional 105 shares during the quarter. Albion Financial Group UT’s holdings in LeMaitre Vascular were worth $295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of LeMaitre Vascular by 11,612.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 3,716 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new position in shares of LeMaitre Vascular in the second quarter worth $137,000. Royce & Associates LP purchased a new position in shares of LeMaitre Vascular in the second quarter worth $156,000. Royal Bank of Canada raised its stake in shares of LeMaitre Vascular by 856.5% in the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 4,505 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its stake in shares of LeMaitre Vascular by 4,751.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,355 shares of the medical instruments supplier’s stock worth $198,000 after purchasing an additional 6,224 shares during the last quarter. Hedge funds and other institutional investors own 66.34% of the company’s stock.

LeMaitre Vascular, Inc. (LMAT) traded down 0.147% on Thursday, hitting $37.375. The stock had a trading volume of 17,916 shares. The firm has a market cap of $710.95 million, a PE ratio of 53.393 and a beta of 0.67. The company has a 50-day moving average price of $37.29 and a 200 day moving average price of $31.56. LeMaitre Vascular, Inc. has a 52-week low of $18.55 and a 52-week high of $39.29.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/lemaitre-vascular-inc-lmat-stake-lifted-by-albion-financial-group-ut/1707389.html

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million during the quarter, compared to analyst estimates of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the business posted $0.14 EPS. Equities analysts forecast that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular declared that its board has authorized a share buyback plan on Thursday, July 27th that authorizes the company to buyback $7.50 million in shares. This buyback authorization authorizes the medical instruments supplier to buy up to 1.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: This news story was published by Zolmax and is owned by of Zolmax. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://zolmax.com/investing/lemaitre-vascular-inc-lmat-stake-lifted-by-albion-financial-group-ut/1707389.html.

Several research analysts have recently weighed in on LMAT shares. BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price target (up previously from $29.00) on shares of LeMaitre Vascular in a research note on Sunday, July 30th. Canaccord Genuity restated a “hold” rating and issued a $30.00 price target on shares of LeMaitre Vascular in a research note on Monday. Finally, Benchmark Co. cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Monday, July 10th. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus target price of $32.00.

In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 58,700 shares of LeMaitre Vascular stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $33.97, for a total transaction of $1,994,039.00. Following the completion of the transaction, the chairman now owns 3,471,808 shares in the company, valued at approximately $117,937,317.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter R. Gebauer sold 22,067 shares of LeMaitre Vascular stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $34.28, for a total value of $756,456.76. Following the transaction, the insider now owns 4,486 shares of the company’s stock, valued at approximately $153,780.08. The disclosure for this sale can be found here. Insiders have sold a total of 373,121 shares of company stock valued at $12,825,992 in the last quarter. Company insiders own 23.70% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bco Com Portugues  Given Consensus Rating of “Sell” by Analysts
Bco Com Portugues Given Consensus Rating of “Sell” by Analysts
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc.  Stock
GSA Capital Partners LLP Invests $258,000 in Aerie Pharmaceuticals, Inc. Stock
Crestwood Equity Partners LP  Shares Sold by GSA Capital Partners LLP
Crestwood Equity Partners LP Shares Sold by GSA Capital Partners LLP
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc.  Stock
GSA Capital Partners LLP Invests $270,000 in Sabra Healthcare REIT, Inc. Stock
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
Citigroup Inc. Buys 897 Shares of WisdomTree Internationl Dvdnd Ex Fncl Fd
First Bancorp  Shares Sold by GSA Capital Partners LLP
First Bancorp Shares Sold by GSA Capital Partners LLP


Leave a Reply

 
© 2006-2017 Zolmax.